Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
SenzaGen AB
SenzaGen AB
Activities:
Regulatory
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
SenzaGen and MB Research Labs sign toxicology agreement
With new legislature, animal-free <em>in vitro</em> toxicological testing is a growing market in the US. This collaboration taps into this market
Analysis
Next-generation safety testing
In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Pharmaceutical
Swedish SenzaGen teams up with Chinese animal-free testing specialist
The partnership comes at a time when a ban on animal experiments is expected
SenzaGen strengthens its organisation with IR and communications director
Recruitment
SenzaGen recruits Business Development Director
Research & Development
Collaboration tackles respiratory irritancy hazard
SenzaGen and AstraZeneca will develop a new genomic signature to distinguish allergens from irritants in the respiratory tract
Subscribe now